Tumor-Targeting Therapy Using Gene-Engineered Anaerobic-Nonpathogenic Bifidobacterium longum
The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Abstract
Despite great progress in molecular-targeting drugs for cancer treatment, there are problems of disease recurrence due to cancer-cell resistance to those drugs, derived from the heterogeneity of tumors. On one hand, the low-oxygen microenvironment present in malignant tumor tissues has been regarded as a source of resistance of cancer cells against conventional therapie, such as radiation and chemotherapy. To overcome these problems, we have been developing a system to selectively deliver a large amount of anticancer drugs to malignant tumors by making use of the limiting factor, hypoxia, in tumors. Our strategy is to use hypoxia as a selective target. Here, we show methods and protocols using the nonpathogenic obligate anaerobic Bifidobacterium longum as a drug-delivery system (DDS) to target anaerobic tumor tissue.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“To date, genetically attenuated, nutrient deficient, and inducible Escherichia coli [146], Bifidobacteria [147], Listeria [148], and Salmonella [148] have been transformed and have shown antitumor effects in preclinical models of intravenous, intratumoral, and oral administration routes [149].”
From Gut microbiota influence immunotherapy responses: mechanisms and therapeutic strategies (2022) · doi:10.1186/s13045-022-01273-9 · cites this paper as [147]
Citations
Cites
Cycling hypoxia and free radicals regulate angiogenesis and radiotherapy response
Dewhirst, M. W., Cao, Y., & Moeller, B. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2397 · Cited by 1,022
Engineering the perfect (bacterial) cancer therapy
Forbes, N. S. (2010) · Nature Reviews Cancer · doi:10.1038/nrc2934 · Cited by 905
Toso, J. F. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.20.1.142 · Cited by 614
Hypoxia-driven selection of the metastatic phenotype
Sullivan, R., & Graham, C. H. (2007) · Cancer and Metastasis Reviews · doi:10.1007/s10555-007-9062-2 · Cited by 410
Gueniche, A., Knaudt, B., Schuck, E., Volz, T., Bastien, P., Martin, R., Röcken, M., Breton, L., & Biedermann, T. (2008) · British Journal of Dermatology · doi:10.1111/j.1365-2133.2008.08836.x · Cited by 247
Yazawa, K., Fujimori, M., Amano, J., Kano, Y., & Taniguchi, S. (2000) · Cancer Gene Therapy · doi:10.1038/sj.cgt.7700122 · Cited by 241
Self-citationYazawa, K., Fujimori, M., Nakamura, T., Sasaki, T., Amano, J., Kano, Y., & Taniguchi, S. (2001) · Breast Cancer Research and Treatment · doi:10.1023/a:1010644217648 · Cited by 161
Self-citationBacterial targeted tumour therapy-dawn of a new era
Wei, M. Q., Mengesha, A., Good, D., & Anné, J. (2008) · Cancer Letters · doi:10.1016/j.canlet.2007.10.034 · Cited by 159
Kimura, N. T., Taniguchi, S., Aoki, K., & Baba, T. (1980) · PubMed · Cited by 153
Self-citationSasaki, T., Fujimori, M., Hamaji, Y., Hama, Y., Ito, K., Amano, J., & Taniguchi, S. (2006) · Cancer Science · doi:10.1111/j.1349-7006.2006.00221.x · Cited by 127
Self-citation
Cited by
Gut microbiota influence immunotherapy responses: mechanisms and therapeutic strategies
(2022) · doi:10.1186/s13045-022-01273-9 · Cited by 495
Bioengineered and biohybrid bacteria-based systems for drug delivery
Hosseinidoust, Z., Mostaghaci, B., Yasa, O., Park, B.-W., Singh, A. V., & Sitti, M. (2016) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2016.09.007 · Cited by 368
Recent Development of Probiotic Bifidobacteria for Treating Human Diseases
Chen, J., Chen, X., & Ho, C. L. (2021) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2021.770248 · Cited by 241
Camouflaging bacteria by wrapping with cell membranes
Cao, Z., Cheng, S., Wang, X., Pang, Y., & Liu, J. (2019) · Nature Communications · doi:10.1038/s41467-019-11390-8 · Cited by 249
Cell primitive-based biomimetic functional materials for enhanced cancer therapy
Luo, G.-F., Chen, W.-H., Zeng, X., & Zhang, X.-Z. (2021) · Chemical Society Reviews · doi:10.1039/d0cs00152j · Cited by 193
Metadata
- Authors
- Taniguchi, S., Shimatani, Y., & Fujimori, M.
- Affiliations
- Shinshu University (JP)
- Anaeropharma Science (Japan) (JP)
- Tokyo Medical University Ibaraki Medical Center (JP)
- Corresponding author
- Taniguchi, Shun’ichiro
- Venue
- Methods in Molecular Biology
- Publisher
- Springer New York
- Published
- 2016
- Volume
- 1409
- Pages
- 49-60
- ISSN
- 1064-3745 (ISSN-L)
- 1940-6029
- OpenAlex
- W2402708936
- Cited by
- 41
- References
- 14
- Citations by year
- 2026: 3 · 2025: 7 · 2024: 5 · 2022: 4 · 2021: 4 · 2020: 6 · 2019: 8 · 2018: 1 · 2017: 1 · 2016: 2
- FWCI
- 5.45
- Type
- book chapter
- Language
- en
- Open access
- closed
- Locations
- Methods in molecular biology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biotechnology › Bacterial Cancer Therapy
- Life Sciences › Agricultural and Biological Sciences › Food Science › Probiotics and Fermented Foods
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Hypoxia, and Metabolism
- Keywords
- Bifidobacterium longum, hypoxia, tumor hypoxia, drug delivery systems, non-pathogenic bacteria, obligate anaerobes, anticancer drug delivery, tumor heterogeneity, chemoresistance, radioresistance (biology)
- MeSH terms
- Animals, Hypoxia, Bifidobacterium, Disease Models, Animal, Genetic Engineering, Humans, Immunohistochemistry, Male, Neoplasms, Oxygen Consumption, Transplantation, Isogeneic, Drug Delivery Systems, Xenograft Model Antitumor Assays, Mice, Rats
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Tumor-Targeting Therapy Using Gene-Engineered Anaerobic-Nonpathogenic Bifidobacterium longum. https://app.cochat.ai/papers/10.1007/978-1-4939-3515-4_5
- The paper
- Taniguchi, S., Shimatani, Y., & Fujimori, M. (2016). Tumor-Targeting Therapy Using Gene-Engineered Anaerobic-Nonpathogenic Bifidobacterium longum. Methods in Molecular Biology. https://doi.org/10.1007/978-1-4939-3515-4_5
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.